Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Dec 8;82(1):34–38. doi: 10.1054/bjoc.1999.0873

Depletion of protein kinase C (PKC) by 12- O -tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells

S Isonishi 1, K Ohkawa 2, T Tanaka 1, S B Howell 3
PMCID: PMC2363215  PMID: 10638963

Abstract

Down-regulation of protein kinase C (PKC) by 12- O -tetradecanoylphorbol-13-acetate (TPA) enhances the sensitivity of human ovarian carcinoma 2008 cells to various types of platinum compounds such as cisplatin (DDP), carboplatin and (–)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato)-platinum(II) monohydrate (DWA) by a factor of two- to threefold. TPA enhanced the sensitivity of the DDP-resistant 2008/C13*5.25 subline to each of these three drugs to the same extent as for the 2008 cells. The extent of PKC down-regulation and drug sensitization depended on the duration of TPA exposure; maximum effect was achieved with a 48 h pretreatment. Sensitization was TPA concentration-dependent and was maximal at 0.05 μM TPA. 2008 cells expressed only the PKCα and PKCζ isoforms. Western blot analysis revealed that whereas the expression of PKCα was reduced by TPA the level of PKCζ was not affected. These results suggest that PKCα is the isotype responsive to TPA in these cells and that platinum drug sensitivity can be modulated by this isoform alone. In parallel to its effect on PKCα, TPA decreased cellular glutathione content by 30 ± 3 (standard deviation (s.d.) % in 2008 cells and by 41 ± 3 (s.d.) % in 2008/C13*5.25 cells. TPA also increased accumulation of DDP and DWA by 70%, although this effect was limited to the 2008/C13*5.25 cells. TPA rendered 2008 and 2008/C13*5.25 cells resistant to cadmium chloride by a factor of 3.7 and 3.6-fold respectively, suggesting a significant increase in cellular metallothionein content. Although the mechanism of TPA induced sensitization is not yet fully understood, this study points to a central role for PKCα in modulating platinum drug sensitivity. © 2000 Cancer Research Campaign

Keywords: platinum agents, protein kinase C, drug sensitivity

Full Text

The Full Text of this article is available as a PDF (80.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. A., Howell S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990 Feb;2(2):35–43. [PubMed] [Google Scholar]
  2. Andrews P. A., Murphy M. P., Howell S. B. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res. 1985 Dec;45(12 Pt 1):6250–6253. [PubMed] [Google Scholar]
  3. Balboa M. A., Firestein B. L., Godson C., Bell K. S., Insel P. A. Protein kinase C alpha mediates phospholipase D activation by nucleotides and phorbol ester in Madin-Darby canine kidney cells. Stimulation of phospholipase D is independent of activation of polyphosphoinositide-specific phospholipase C and phospholipase A2. J Biol Chem. 1994 Apr 8;269(14):10511–10516. [PubMed] [Google Scholar]
  4. Basu A., Teicher B. A., Lazo J. S. Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). J Biol Chem. 1990 May 25;265(15):8451–8457. [PubMed] [Google Scholar]
  5. Blagosklonny M. V., Prabhu N. S., El-Deiry W. S. Defects in p21WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res. 1997 Jan 15;57(2):320–325. [PubMed] [Google Scholar]
  6. Brach M. A., Herrmann F., Kufe D. W. Activation of the AP-1 transcription factor by arabinofuranosylcytosine in myeloid leukemia cells. Blood. 1992 Feb 1;79(3):728–734. [PubMed] [Google Scholar]
  7. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  8. Bruder J. T., Heidecker G., Rapp U. R. Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase. Genes Dev. 1992 Apr;6(4):545–556. doi: 10.1101/gad.6.4.545. [DOI] [PubMed] [Google Scholar]
  9. Chambers T. C., McAvoy E. M., Jacobs J. W., Eilon G. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem. 1990 May 5;265(13):7679–7686. [PubMed] [Google Scholar]
  10. Chmura S. J., Nodzenski E., Weichselbaum R. R., Quintans J. Protein kinase C inhibition induces apoptosis and ceramide production through activation of a neutral sphingomyelinase. Cancer Res. 1996 Jun 15;56(12):2711–2714. [PubMed] [Google Scholar]
  11. Craven P. A., DeRubertis F. R. Role of activation of protein kinase C in the stimulation of colonic epithelial proliferation by unsaturated fatty acids. Gastroenterology. 1988 Sep;95(3):676–685. doi: 10.1016/s0016-5085(88)80014-3. [DOI] [PubMed] [Google Scholar]
  12. DiSaia P. J., Sinkovics J. G., Rutledge F. N., Smith J. P. Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors. Am J Obstet Gynecol. 1972 Dec 1;114(7):979–989. doi: 10.1016/0002-9378(72)90109-3. [DOI] [PubMed] [Google Scholar]
  13. Fine R. L., Patel J., Chabner B. A. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci U S A. 1988 Jan;85(2):582–586. doi: 10.1073/pnas.85.2.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fung H., Quinlan T. R., Janssen Y. M., Timblin C. R., Marsh J. P., Heintz N. H., Taatjes D. J., Vacek P., Jaken S., Mossman B. T. Inhibition of protein kinase C prevents asbestos-induced c-fos and c-jun proto-oncogene expression in mesothelial cells. Cancer Res. 1997 Aug 1;57(15):3101–3105. [PubMed] [Google Scholar]
  15. Gately D. P., Howell S. B. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer. 1993 Jun;67(6):1171–1176. doi: 10.1038/bjc.1993.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Godwin A. K., Meister A., O'Dwyer P. J., Huang C. S., Hamilton T. C., Anderson M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3070–3074. doi: 10.1073/pnas.89.7.3070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hsu S. L., Chou Y. H., Yin S. C., Liu J. Y. Differential effects of phorbol ester on growth and protein kinase C isoenzyme regulation in human hepatoma Hep3B cells. Biochem J. 1998 Jul 1;333(Pt 1):57–64. doi: 10.1042/bj3330057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Isonishi S., Andrews P. A., Howell S. B. Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem. 1990 Mar 5;265(7):3623–3627. [PubMed] [Google Scholar]
  19. Isonishi S., Hom D. K., Eastman A., Howell S. B. Enhancement of sensitivity to platinum(II)-containing drugs by 12-O-tetradecanoyl-phorbol-13-acetate in a human ovarian carcinoma cell line. Br J Cancer. 1994 Feb;69(2):217–221. doi: 10.1038/bjc.1994.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kelley S. L., Basu A., Teicher B. A., Hacker M. P., Hamer D. H., Lazo J. S. Overexpression of metallothionein confers resistance to anticancer drugs. Science. 1988 Sep 30;241(4874):1813–1815. doi: 10.1126/science.3175622. [DOI] [PubMed] [Google Scholar]
  21. Kolch W., Heidecker G., Kochs G., Hummel R., Vahidi H., Mischak H., Finkenzeller G., Marmé D., Rapp U. R. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature. 1993 Jul 15;364(6434):249–252. doi: 10.1038/364249a0. [DOI] [PubMed] [Google Scholar]
  22. Kondo Y., Woo E. S., Michalska A. E., Choo K. H., Lazo J. S. Metallothionein null cells have increased sensitivity to anticancer drugs. Cancer Res. 1995 May 15;55(10):2021–2023. [PubMed] [Google Scholar]
  23. Loehrer P. J., Einhorn L. H. Drugs five years later. Cisplatin. Ann Intern Med. 1984 May;100(5):704–713. doi: 10.7326/0003-4819-100-5-704. [DOI] [PubMed] [Google Scholar]
  24. McCaffrey P., Ran W., Campisi J., Rosner M. R. Two independent growth factor-generated signals regulate c-fos and c-myc mRNA levels in Swiss 3T3 cells. J Biol Chem. 1987 Feb 5;262(4):1442–1445. [PubMed] [Google Scholar]
  25. Niedel J. E., Kuhn L. J., Vandenbark G. R. Phorbol diester receptor copurifies with protein kinase C. Proc Natl Acad Sci U S A. 1983 Jan;80(1):36–40. doi: 10.1073/pnas.80.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ozols R. F., Young R. C. Chemotherapy of ovarian cancer. Semin Oncol. 1984 Sep;11(3):251–263. [PubMed] [Google Scholar]
  27. Rahmsdorf H. J., Herrlich P. Regulation of gene expression by tumor promoters. Pharmacol Ther. 1990;48(2):157–188. doi: 10.1016/0163-7258(90)90079-h. [DOI] [PubMed] [Google Scholar]
  28. Rapp U. R. Role of Raf-1 serine/threonine protein kinase in growth factor signal transduction. Oncogene. 1991 Apr;6(4):495–500. [PubMed] [Google Scholar]
  29. Reed D. J., Babson J. R., Beatty P. W., Brodie A. E., Ellis W. W., Potter D. W. High-performance liquid chromatography analysis of nanomole levels of glutathione, glutathione disulfide, and related thiols and disulfides. Anal Biochem. 1980 Jul 15;106(1):55–62. doi: 10.1016/0003-2697(80)90118-9. [DOI] [PubMed] [Google Scholar]
  30. Schilder R. J., Ozols R. F. New therapies for ovarian cancer. Cancer Invest. 1992;10(4):307–315. doi: 10.3109/07357909209032755. [DOI] [PubMed] [Google Scholar]
  31. Smeal T., Binetruy B., Mercola D., Grover-Bardwick A., Heidecker G., Rapp U. R., Karin M. Oncoprotein-mediated signalling cascade stimulates c-Jun activity by phosphorylation of serines 63 and 73. Mol Cell Biol. 1992 Aug;12(8):3507–3513. doi: 10.1128/mcb.12.8.3507. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES